Biomimetic nanoparticles for gas production and anti-tumor activity catalyzed by bioenzymes and preparation method thereof

A biomimetic nano-anti-tumor technology, applied in anti-tumor drugs, drug combinations, pharmaceutical formulations, etc., to achieve good biocompatibility, reduce toxic and side effects, and improve curative effect

Active Publication Date: 2019-06-07
NANJING UNIV OF TECH
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] CN108721321A, CN108434462A, etc. disclose the application of manganese carbonyl compound (M

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomimetic nanoparticles for gas production and anti-tumor activity catalyzed by bioenzymes and preparation method thereof
  • Biomimetic nanoparticles for gas production and anti-tumor activity catalyzed by bioenzymes and preparation method thereof
  • Biomimetic nanoparticles for gas production and anti-tumor activity catalyzed by bioenzymes and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] (1) Dissolve 5 mg of glucose oxidase in 0.5 ml of water to prepare a glucose oxidase solution with a concentration of 10 mg / mL; dissolve 2 mg of manganese carbonyl compound and 100 mg of polylactic acid-glycolic acid copolymer in 5 mL of organic solution to prepare Manganese carbonyl compound (0.4mg / mL)-polylactic acid-glycolic acid (20mg / mL) solution; pre-cool all solutions in an environment of 1-5°C, and set aside.

[0051] (2) Take 500 μL of glucose oxidase solution and add it to the manganese carbonyl compound-polylactic acid-glycolic acid solution in step (1), perform ultrasonic emulsification for 30 s, and the ultrasonic emulsification power is 300 W, and prepare W / O colostrum for later use.

[0052] (3) Immediately transfer the colostrum obtained in step (2) into 5 mL of 2% polyvinyl alcohol (PVA) solution, and perform ultrasonic emulsification for 2 minutes with a ultrasonic emulsification power of 200 W to prepare a W / O / W double emulsion. spare.

[0053] (4) A...

Embodiment 2

[0057] PLGA nanocarriers (MGP) and red blood cell membrane-wrapped PLGA nanocarriers (MGP@RBC) were prepared according to the method in Example 1, and PLGA nanocarriers (MGP), red blood cell membrane-wrapped PLGA nanocarriers (MGP@RBC) and red blood Membrane (RBC) was made into a solution with a concentration of 500μg / mL with deionized water, and then its particle size was measured at 37°C.

[0058] The particle size results of the two nanocarriers and the red blood cell membrane are as follows figure 1 As shown, the particle size of red blood cell membrane (RBC) is 180±4nm; the particle size of PLGA nanocarrier (MGP) is 145±2nm; the particle size of red blood cell membrane-wrapped PLGA nanocarrier (MGP@RBC) is 155.0±4nm. The results showed that the particle size of PLGA nanocarriers wrapped in red blood cell membrane (MGP@RBC) became larger, which proved the successful wrapping of red blood cell membrane.

Embodiment 3

[0060] PLGA nanocarriers (MGP) and red blood cell membrane-wrapped PLGA nanocarriers (MGP@RBC) were prepared according to the method in Example 1, and PLGA nanocarriers (MGP), red blood cell membrane-wrapped PLGA nanocarriers (MGP@RBC) and red blood cell Membrane (RBC) was made into a solution with a concentration of 500 μg / mL with deionized water, and then its potential was measured at 37 °C.

[0061] The results of two nanocarriers and erythrocyte membrane potential are as follows figure 2 As shown, the potential of red blood cell membrane (RBC) is -7.8±2mV; the potential of PLGA nanocarrier (MGP) is -17.4±2mV; the potential of red blood cell membrane-wrapped PLGA nanocarrier (MGP@RBC) is -8.2±2nm. The results showed that the potential of the erythrocyte membrane-wrapped PLGA nanocarrier (MGP@RBC) presented the potential of the red blood cell membrane (RBC), which proved the successful wrapping of the red blood cell membrane.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to biomimetic nanoparticles for gas production and anti-tumor activity catalyzed by bioenzymes and a preparation method thereof. Firstly, MnCO (Manganese carbonyl compounds) areloaded on a PLGA (polylactic acid-glycolic acid) solution, GOX (glucose oxidase) is embedded in the above mentioned system, a MnCO-PLGA nano solution embedded with GOX is prepared through volatilization of an emulsified solvent, GOX-MnCO-PLGA is squeezed into vesicles derived from erythrocyte membranes, and the biomimetic nanoparticles for gas production and anti-tumor activity catalyzed by bioenzymes. The prepared biomimetic nanoparticles provide a novel tumor treatment strategy, a gas therapy and a hunger therapy are synergistically used, and erythrocyte membranes serve as nanoparticle capsids, so that the prepared biomimetic nanoparticles can control formation of carbon monoxide in situ in tumor target tissues and have good anti-tumor effects.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a biological enzyme-catalyzed gas-producing anti-tumor biomimetic nanoparticle and a preparation method thereof. Background technique [0002] Cancer is one of the most serious public health problems worldwide. Current cancer treatment methods include radiotherapy, chemotherapy, photodynamic therapy, and photothermal therapy. However, the killing effect of these methods on cancer cells is very limited, and the adverse toxicity to normal cells is a common problem of these therapeutic measures, which hinders their effective application in cancer therapy. Most antitumor drugs have poor solubility, are prone to multidrug resistance, and can cause irreversible damage to normal human tissues, affecting the therapeutic effect of cancer and the quality of life of patients. Therefore, it is urgent to develop an anti-tumor method with high efficiency and low toxicity to meet th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/51A61K47/34A61K47/46A61K38/44A61K31/7135A61P35/00
Inventor 李学明任浩王雨倩王永禄孟政杰陈卫王栋
Owner NANJING UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products